Abstract
Although the incidence of gastric cancer has been declining in Western countries, it is still a major health problem and a leading cause of cancer mortality. Surgery is the mainstay of treatment for gastric adenocarcinoma. However, even among patients undergoing gastrectomy with curative intent, 5-year survival rates are disappointing due to locoregional relapse and distant metastases. This emphasizes the importance of multidisciplinary management of patients with gastric cancer. In contrast to the preoperative approach, several phase III trials have been carried out in the adjuvant setting, but postoperative chemotherapy has not proven to be superior to surgery alone. Therefore, at present the routine use of adjuvant therapy should be regarded as an investigational approach. Improved clinical trial designs with standardized surgical techniques and the incorporation of newer active drugs are needed.
Citations
Feb 18, 2011·Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association·Amy T Y ChangAnne W M Lee
Aug 17, 2011·Investigational New Drugs·Byung Woog KangWansik Yu
Mar 11, 2011·World Journal of Gastroenterology : WJG·Jun-Duo HuJin-Lian Chen
Jan 24, 2014·Oncology Reports·Frank HenselBertram Illert
Feb 4, 2014·Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association·Elodie HerbreteauAnne-Marie Bouvier
Apr 15, 2014·Cancer Genetics·Lifeng MiaoNansheng Cheng
Nov 28, 2015·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Jie WuCheng Dong
Aug 22, 2012·The Journal of International Medical Research·Y Y WangJ-H Wang
Aug 7, 2019·Scandinavian Journal of Gastroenterology·Xu ZhangJun Lyu
Nov 9, 2018·Oncology Letters·Rui SongZongwen Liu
Oct 17, 2012·Molecular and Cellular Biochemistry·Jialing ZhongChangzhi Huang
Aug 31, 2016·Oncology Reports·Jianbo XiongHeping Chen
Dec 4, 2012·Oncology Letters·Sheng-Liu XueCong-Ying Xie
Jul 18, 2017·International Journal of Oncology·Meizhong XuMengnan Li